-
Jan 23, 2025 | 
ascopost.com | Alice Goodman
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy).
-
Jan 22, 2025 | 
ascopost.com | Alice Goodman
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with endocrine therapy–pretreated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
-
Jan 10, 2025 | 
ascopost.com | Alice Goodman
Adjuvant tamoxifen was associated with a reduced risk of 15-year ipsilateral breast cancer recurrence as well as invasive ipsilateral breast cancer recurrence in patients with “good-risk” ductal carcinoma in situ (DCIS) who omitted radiation therapy after breast-conserving surgery, according to a combined analysis of the phase III NRG Oncology/RTOG 9804 and the phase II ECOG-ACRIN E5194 trials.
-
Jan 8, 2025 | 
ascopost.com | Alice Goodman
For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with placebo, according to the third interim analysis of the phase III OlympiA trial presented at the 2024 San Antonio Breast Cancer Symposium.1 The benefits of olaparib were evident in patients with triple-negative breast cancer and in those with estrogen receptor (ER)-positive breast cancer, after a...
-
Jan 7, 2025 | 
ascopost.com | Alice Goodman
Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, according to late-breaking results from the phase III AFT-38 PATINA trial presented at the 2024 San Antonio Breast Cancer Symposium.1 Median progression-free...
-
Jan 6, 2025 | 
ascopost.com | Alice Goodman
Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing surgeries, including bilateral mastectomy and/or salpingo-oophorectomy, according to data presented at the 2024 San Antonio Breast Cancer Symposium.1 For those who had risk-reducing mastectomy, at 5 years, they had a 35% reduced risk of dying, and both disease-free survival and breast...
-
Sep 8, 2024 | 
ascopost.com | Alice Goodman
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of lymph node–only metastases (ie, cN+ urothelial cancer), providing optimism that patients with this type of urothelial carcinoma may achieve long-term remission.
-
Jul 24, 2024 | 
ascopost.com | Alice Goodman
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), who typically have poor outcomes.
-
Jul 9, 2024 | 
ascopost.com | Alice Goodman
The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was associated with increased gastrointestinal side effects and fatigue.
“Unfortunately, there was no benefit for metformin in this particular group of patients, and that is disappointing.
-
Jul 9, 2024 | 
ascopost.com | Alice Goodman
The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, according to the results of OptiTROP-Breast01, a phase III study presented at the 2024 ASCO Annual Meeting.1 “The clinical benefits were consistent and independent of TROP2 expression; however, a trend was observed toward longer progression-free survival in patients with high TROP2 expression,”...
